After more than 25 years in drug development that culminated in a corner office at Calistoga Pharmaceuticals, Carol Gallagher decamped for the venture world last year, and now she has accepted a position at New Enterprise Associates to help nurture the next generation of disruptive biotechs.
Rescued from Pfizer's sweeping R&D cuts, Levicept's lead drug is a protein with promise in chronic pain, and the biotech has raised $15.7 million in venture and grant funding to follow through on its potential.
It's better to be lucky than smart, but to be among the best life sciences investors it helps to be both. We've compiled a list of public company investors who have managed to outperform the...
Closely allied with Eli Lilly, TVM Capital Life Sciences has bumped up its latest fund past the $200 million mark with plans to bankroll up to 15 build-to-buy drug development projects.
The Netherlands' Forbion Capital Partners has wrapped up the first close in a planned third fund, raking in $120 million with plans to stake a new generation of biotechs.
For the past 35 years, Atlas Venture has operated as a diversified investor, splitting its efforts between technology and life sciences. Starting next year, the two sides will part.
European venture outfit LSP (Life Sciences Partners) has raised $100 million toward a new biotech fund, setting out to stake a dozen or so innovators in drugs, devices and diagnostics.
A slate of top-tier biotech investors are coming in with a whopping $104 million Series A designed to take Oxford-based Adaptimmune--named a Fierce 15 company earlier in the week--well down the clinical path on its immuno-oncology tech.
Back at the beginning of this month, Seattle-based VentiRx spread the news that it had raised a venture round for its newly fast-tracked TLR8 cancer vaccine research, but didn't disclose just how much it had in hand. A new filing at the SEC, though, puts the venture figure at $50.6 million, with another $2.4 million or so left to add in the planned raise.
Eight months after partnering with Novartis, Emeryville, CA-based Eureka Therapeutics has landed a $21 million round led by a Chinese private equity firm. Beijing-based Yuan Capital led the round, with Majuven and all the current major investors, including Acorn Campus Ventures, Suma Venture and Harbinger Venture Capital, joining in.